Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R. Ferenci P, et al. Among authors: bondin m. J Viral Hepat. 2019 Jun;26(6):685-696. doi: 10.1111/jvh.13080. Epub 2019 Mar 5. J Viral Hepat. 2019. PMID: 30739368 Free PMC article.
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.
Poordad F, Castro RE, Asatryan A, Aguilar H, Cacoub P, Dieterich D, Marinho RT, Carvalho A, Siddique A, Hu YB, Charafeddine M, Bondin M, Khan N, Cohen DE, Felizarta F. Poordad F, et al. Among authors: bondin m. J Viral Hepat. 2020 May;27(5):497-504. doi: 10.1111/jvh.13261. Epub 2020 Feb 17. J Viral Hepat. 2020. PMID: 31954087 Clinical Trial.
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
Feld JJ, Forns X, Dylla DE, Kumada H, de Ledinghen V, Wei L, Brown RS Jr, Flisiak R, Lampertico P, Thabut D, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Jacobson IM. Feld JJ, et al. Among authors: bondin m. J Viral Hepat. 2022 Dec;29(12):1050-1061. doi: 10.1111/jvh.13738. Epub 2022 Oct 6. J Viral Hepat. 2022. PMID: 36036117 Free PMC article.
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
Forns X, Feld JJ, Dylla DE, Pol S, Chayama K, Hou J, Heo J, Lampertico P, Brown A, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Gordon SC, Jacobson IM. Forns X, et al. Among authors: bondin m. Adv Ther. 2021 Jun;38(6):3409-3426. doi: 10.1007/s12325-021-01753-3. Epub 2021 May 22. Adv Ther. 2021. PMID: 34021887 Free PMC article.
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Fontana RJ, Lens S, McPherson S, Elkhashab M, Ankoma-Sey V, Bondin M, Dos Santos AGP, Xue Z, Trinh R, Porcalla A, Zeuzem S. Fontana RJ, et al. Among authors: bondin m. Adv Ther. 2019 Dec;36(12):3458-3470. doi: 10.1007/s12325-019-01123-0. Epub 2019 Oct 23. Adv Ther. 2019. PMID: 31646465 Free PMC article.
21 results